Sight Sciences director buys 14,100 shares
Sight Sciences director and 10% owner Staffan Encrantz reported an open-market purchase of 14,100 shares of Common Stock at a weighted average price of $4.879 per share.
Rhea-AI Filing Summary
Sight Sciences director and 10% owner Staffan Encrantz reported an open-market purchase of 14,100 shares of Common Stock at a weighted average price of $4.879 per share. After this trade, he directly holds 1,434,283 shares, including 28,261 restricted stock units subject to vesting as previously reported.
He also reports indirect interests in 5,086,920 shares held by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust, where he is a trustee, and 632,456 shares held by Allegro Investment Fund, L.P. He disclaims beneficial ownership of Allegro’s shares and of the trust and fund holdings beyond any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 14,100 | $4.879 | $69K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (4)
- F1. The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased in multiple transactions at per share prices ranging from $4.78 to $4.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2. Includes (i)1,406,022 shares of Common Stock and (ii) 28,261 restricted stock units, which restricted stock units are subject to vesting as previously reported.
- F3. These shares of Common Stock are held of record by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust (the "Trust"). The Reporting Person is a trustee of the Trust and may be deemed to beneficially own the shares held by the Trust for purposes of Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"). The Reporting Person disclaims beneficial ownership of the shares held by the Trust (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 under the Exchange Act or for any other purpose), except to the extent of his pecuniary interest therein, if any.
- F4. These shares of Common Stock are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the Chairman and CEO and sole director of Allegro Investment Inc., which is the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund for purposes of Rule 13d-3 under the Exchange Act. However, the Reporting Person does not have any pecuniary interest in the shares held by Allegro Investment Fund and disclaims beneficial ownership with respect to all such shares. Accordingly, these shares are being reported in this report voluntarily by the Reporting Person for informational purposes only and shall not be deemed an admission that the Reporting Person is the beneficial owner of any such shares for purposes of Section 16 under the Exchange Act or for any other purpose.
Key Figures
Key Terms
restricted stock units financial
Rule 13d-3 regulatory
Section 16 regulatory
pecuniary interest financial
weighted average price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Staffan Encrantz report at Sight Sciences (SGHT)?
What indirect Sight Sciences (SGHT) holdings are associated with Staffan Encrantz?
AI-generated analysis. How Rhea-AI works. Not financial advice.